Over the course of the past month, clinical stage life sciences company Cardiol Therapeutics Inc (TSE:CRDL) (NASDAQ:CRDL) has seen its stock emerge as one of the stronger performers in the sector. During that period, the stock attracted significant attention from investors and ended up clocking gains of as much as 30%.
Trading Data
In the morning session, CRDL stock fell 6.06% to close at $2.17 with more than 416k shares traded, compared to its average volume of 777k shares. The stock has moved within a range of $2.0900 – 2.3600 after opening trading at $2.35.
Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
This morning, the stock could well come into focus among investors after it made a key announcement. Cardiol announced this morning that it had made as many as three new appointments to its scientific advisory board. Appointments to that particular body are almost always important.
The company inducted Joseph A Hill, MD, PhD, Paul M Ridker, MD, MPH and Bruce McManus, PhD, MD to the Scientific Advisory Board. The Chief Executive Officer and President of the company David Elsley spoke about the appointment as well. He stated that everyone at the company was pleased at the opportunity to add the expertise of three highly accomplished ‘thought leaders’ from the field of cardiovascular medicine.
He went on to add that their expertise will help the company in taking forward its own work in the field of cardiovascular research. It may be a good time for investors to consider keeping an eye on the Cardiol stock today.
Key Quote
“We are pleased to welcome distinguished thought leaders in cardiovascular medicine to our Scientific Advisory Board,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “Their expertise in cardiovascular research will provide invaluable guidance to our research and clinical programs focused on the development of novel anti-inflammatory therapies for the treatment of heart disease.”
Technical Data
CRDL stock is trading above the 20-Day and 50-Day Moving averages of $1.93 and $2.04 respectively. However, the stock is trading below the 200-Day moving average of $2.81.
